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Introduction
Worldwide, leukemia, multiple myeloma (MM), Hodgkin 
lymphoma (HL), and non- Hodgkin lymphoma (NHL) 
collectively accounted for an estimated 6.5% of new cancer 
cases in 2012 with the majority of these cases coming 
from NHL followed by leukemia [1]. While global esti-
mates suggest two and threefold higher incidence rates 
of NHL and leukemia, respectively, in high income coun-
tries compared to Sub- Saharan Africa [1], there is little 
known about the incidence patterns of hematologic 
malignancies in this region, including South Africa. Similar 
to worldwide figures, hematologic malignancies were esti-
mated to contribute about 6% of new cancer cases in 
South Africa in 2012 [1].
To date, the literature of hematologic malignancies in 
South Africa is largely based on hospital- based studies which 
report on patient and disease characteristics of leukemias 
and lymphomas [2–6], with a particular focus on the preva-
lence of HIV and the differences in cancer characteristics 
between HIV- positive and - negative patients. There is a 
well- established association between HIV and several types 
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Abstract
Little is known about the incidence patterns of hematologic malignancies in 
Sub- Saharan Africa, including South Africa. We estimated incidence rates of 
pathology- confirmed adult cases of leukemia, myeloma and related diseases 
(myeloma), Hodgkin lymphoma (HL), and non- Hodgkin lymphoma (NHL) 
reported to the National Cancer Registry of South Africa (NCR) between 2000 
and2006, by age, gender, and population group (Black, White, Coloured, Asian/
Indian). Gender- specific age- standardized rates were calculated overall and by 
population group and incidence rate ratios (IRRs) were estimated using Poisson 
regression models. Between 2000 and 2006, there were 14662 cases of leukemia, 
myeloma, HL, and NHL reported to the registry. Incidence rates of reported 
hematologic malignancies were generally 20–50% higher among males than fe-
males. Our analyses suggested marked differences in the rates of reported he-
matologic malignancies by population group which were most pronounced when 
comparing the White versus Black population groups (IRRs ranging from 1.6 
for myeloma to 3.8 for HL for males and females combined). Challenges related 
to diagnosis and reporting of cancers may play a role in the patterns observed 
by population group while the set- up of the NCR (pathology- based) could lead 
to some degree of under- ascertainment in all groups. This is the first country- 
wide report of the incidence of hematologic malignancies in South Africa. Despite 
challenges, it is important to analyze and report available national cancer inci-
dence data to raise awareness of the cancer burden and to characterize patterns 
by demographic characteristics so as ultimately to improve the provision of 
cancer- related health care.
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of hematologic malignancies, including but not restricted 
to the AIDS- defining subtypes of NHL [7–9]. While hospital- 
based studies benefit from detailed patient information, there 
is also a need to estimate incidence and mortality rates, 
particularly at the national- level. Such data provide important 
information about the overall burden of disease, which in 
turn inform cancer control strategies, and provide a basis 
for investigating underlying determinants of disease.
Studies from the United Kingdom and United States 
show considerable variability in the incidence of hema-
tologic malignancies by gender and age [10–12] as well 
as by population group [10, 11, 13]. It remains unknown 
whether the incidence of these malignancies in South 
Africa follows similar patterns to those reported in higher 
income areas. Recently, it was reported that the incidence 
of pediatric hematologic malignancies was approximately 
three times higher among White compared with Black 
children within South Africa [14]. As population group 
is highly correlated with socioeconomic position and access 
to private health care services in South Africa [15], the 
authors hypothesized that differences in access and utiliza-
tion of health care services likely explain at least some 
of the observed incidence differences [14]. To our knowl-
edge, these patterns have not been investigated among 
adults in South Africa.
In this report, we analyze for the first time the inci-
dence of adult cases of leukemia, multiple myeloma and 
related diseases, HL, and NHL reported to the National 
Cancer Registry of South Africa (NCR) between 2000 and 
2006, by age, gender, and population group.
Material and Methods
National cancer registry
A detailed description of the NCR has been published 
elsewhere [16]. Briefly, the NCR (www.ncr.ac.za) is a 
pathology- based registry, reporting on malignancies con-
firmed in public and private laboratories throughout the 
country. The registry includes only incident, primary invasive 
cancers based on confirmation by histology, cytology, or 
hematology. Trained coders at the NCR code the diagnoses 
from pathology reports based on primary site and mor-
phological type according to the International Classification 
of Diseases for Oncology, third edition (ICD- O- 3) [17]. 
For 2000–2004, the NCR determined cancer diagnosis from 
pathologist reporting of SNOMED codes, rather than full 
pathology reports. For 2005–2006, full pathology reports 
were received from public laboratories but not private. Until 
2011, reporting to the registry was done on a voluntary 
basis although all of the National Health Laboratory Services 
(NHLS) laboratories regularly reported to the registry as 
the NCR is a division of the NHLS. Reporting has been 
less complete from the private sector, particularly from 
2005 onwards [16]. In addition to basic demographic infor-
mation about the patient (name, age and/or date of birth, 
gender) and tumor diagnosis information (topography, 
morphology, date of diagnosis), the registry extracts infor-
mation on population group (Black, White, Coloured (i.e., 
mixed ancestry), and Asian/Indian), where available from 
the pathology reports. If not found on the pathology report, 
a hot- deck imputation method is used to estimate popula-
tion group using a database of approximately 1.4 million 
surnames with known population group [16]. In the dataset 
used for this analysis, 66.8% of the case reports had miss-
ing population group and thus a substantial proportion 
was imputed. If population group cannot be estimated (i.e., 
surname with no match in the database), it is left as miss-
ing. A comparison of the distribution of population group 
based on actual versus imputed data for a subset of 277130 
cancer cases (contributing to the database) reported to the 
registry between 1990 and 1995 showed very good agree-
ment between actual and imputed values. The distribution 
of original versus imputed () data was as follows: 53% 
(50%) White, 40% (41%) Black, 2% (2%) Asian/Indian, 
and 5% (7%) Coloured (chi- squared test P- value = 0.94 
for distribution differences).
Hematologic malignancy cases
For the present report, we included all pathology- confirmed 
incident cases of leukemia, myeloma and related diseases 
(subsequently referred to as myeloma), HL, and NHL 
reported to the NCR that were diagnosed at ages ≥15 years 
between 2000 and 2006. We followed the Surveillance, 
Epidemiology and End Results (SEER) Program site recode 
(http://seer.cancer.gov/siterecode/icdo3_dwhoheme/index.
html) which is based on the ICD- O- 3 [17] and the 2008 
WHO Classification of Tumours of Haematopoietic and 
Lymphoid Tissues [18] for classification of these four 
groups (see Tables 1 and 2 for listing of ICD- O- 3 codes). 
The lack of full pathology reports prevented implementa-
tion of the more detailed classification of lymphoid neop-
slasms [18]. Our analysis did not include hematologic 
malignancies other than leukemia, myeloma, HL, or NHL.
Population data
Consistent with the approach used in the annual reports 
of the NCR for the years included in this study, we used 
the alternative South African mid- year population estimates 
[19] from the Centre for Actuarial Research, University of 
Cape Town, stratified by age, gender, and population group 
for calculation of incidence rates. These mid- year population 
estimates are similar in magnitude to the official mid- year 
estimates, but maintain an age distribution that is consistent 
730 © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
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with that of the most recent census in 2011 and, as with 
the NCR for this time period, we considered them as the 
more appropriate population estimates for the purposes of 
estimating age- specific and age- standardized rates.
Statistical methods
Gender- specific crude incidence rates overall and stratified 
by population group were estimated for leukemia, myeloma, 
HL, and NHL. Reflecting limited case numbers in indi-
vidual age groups, age- specific rates were not estimated 
separately for males and females. Gender- specific age- 
standardized rates, overall and stratified by population 
group, were calculated using the SEGI world standard [20] 
truncated for ages ≥15 (ASR15
+). The ASR15
+ is a weighted 
average of age- specific rates based with the following weights 
for each age group: 15–19 (0.13), 20–24 (0.12), 25–29 
(0.12), 30–34 (0.09), 35–39 (0.09), 40–44 (0.09), 45–49 
(0.09), 50–54 (0.07), 55–59 (0.06), 60–64 (0.06), 65–69 
(0.04), 70–74 (0.03), 75–79 (0.01), and 80+ (0.01).
Incidence rate ratios (IRRs) and 95% confidence intervals 
(CIs) were estimated using Poisson regression models with 
the number of cases for a given category of hematologic 
malignancy as the outcome, the population size as the 
log offset and a log link function, overall and stratified 
by population group, comparing rates among females to 
males. Similar models, overall and stratified by gender, 
were used to compare incidence rates by population group, 
using the Black population group as the reference group. 
All models were adjusted for age group (5 year categories) 
and calendar year (single- year treated as a categorical 
variable). Models including all population groups and/or 
both males and females were further adjusted for popula-
tion group and gender. Hematologic patients with unknown 
population group and/or gender (4.7%) were excluded 
from Poisson models as there were no corresponding 
population estimates for such groups. As under- 
ascertainment of cancers may be more prominent at older 
ages (in many settings)[21], sensitivity analyses were 
repeated by restricting the dataset to ages <75 years.
Results
Between 2000 and 2006, there were a total of 14662 cases 
of leukemia, myeloma, HL, and NHL reported to the registry. 
There were 46 cases (0.3%) with unknown gender. Table 1 
presents the distribution by population group for the 14616 
cases with known gender, by calendar year of diagnosis, 
reporting source (private vs. public), and age at diagnosis, 
separately for males and females. In all calendar years, approxi-
mately half of the cases were reported among the Black, 
33% among the White, 10% among the Coloured, and 5% 
or less among the Asians/Indian population groups. The Ta
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distribution of population group differed substantially between 
public and private laboratories, with the White population 
group accounting for approximately half of all cases reported 
by private laboratories. With increasing age at diagnosis, the 
proportion of cases coming from the Black population group 
declined while that from the White population group increased 
steadily. Similar patterns were observed for males and females 
with respect to calendar year, reporting source and age.
The breakdown of hematologic malignancies types is 
presented for males and females separately, overall and 
by population group, in Figure 1. Regardless of gender 
or population group, NHL was the most commonly 
reported hematologic malignancy, accounting for approxi-
mately 50% or more of cases in most population groups 
(Fig. 1B). In all groups, this was followed by leukemia, 
contributing 15–25% of cases in the various subgroups.
Crude and age- standardized incidence rates are presented 
for leukemia, myeloma, HL, and NHL by population group 
and gender in Table 2. Incidence rates varied markedly 
by population group; in general, the lowest rates were 
observed among the Black population group and the high-
est among the White population group. An exception 
was myeloma, for which rates were lowest among the 
Asian/Indian population group for both males and females.
Figure 1. Distribution of pathology- confirmed cases of hematologic malignancies reported to the National Cancer Registry of South Africa in 
2000–2006 at age ≥15 years for (A) all population groups combined and (B) by population group.
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Figure 2 presents the IRR comparing males to females. 
For all population groups combined, the reported incidence 
rate of hematologic malignancies was 1.2 to 1.5-fold higher 
among males than females (Figure 2a). Similar patterns were 
observed across the four population groups (Figure 2b).
The IRR for population group are presented in Figure 3. 
For males and females combined, reported incidence rates 
of hematologic malignancies tended to be higher among 
the White, Coloured, and Asian/Indian population groups 
than among the Black population group (Fig. 3A). The 
exception was for myeloma, for which no statistically sig-
nificant difference was observed between the Asian/Indian 
and Black population groups, in either males or females. 
The largest rate ratios were observed comparing the White 
Figure 3. Incidence rate ratios of pathology- confirmed hematologic 
malignancies reported to the National Cancer Registry of South Africa in 
2000–2006 comparing the Asian/Indian, Coloured and White 
population groups to the Black population group at age ≥15 years for 
(A) males and females combined, (B) females, and (C) males. Incidence 
rate ratios estimated from Poisson regression model adjusted for age 
(5 year categories), calendar year of diagnosis (1 year categories) and 
gender. Cases with missing gender or population group excluded from 
analyses.
Figure 2. Incidence rate ratios of pathology- confirmed hematologic 
malignancies reported to the National Cancer Registry of South Africa in 
2000–2006 comparing males to females at age ≥15 years for (A) all 
population groups combined and (B) by population group. Incidence 
rate ratios estimated from Poisson regression model adjusted for age 
(5 year categories), calendar year (1 year categories) and population 
group. Cases with missing gender or population group excluded from 
analyses.
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and Black population groups, ranging from 1.56 (95% CI 
1.38–1.76) for myeloma to 3.77 (95% CI 3.38–4.21) for 
HL. Gender- specific patterns were similar to those observed 
for males and females combined (Fig. 3B and C).
Age- specific rates of leukemia, myeloma, HL, and NHL 
are presented in Figure 4A–D by population group. With 
the exception of HL, incidence rates tended to increase 
with age until approximately age 75, followed by a decline 
at the oldest ages. For HL (Fig. 4C), the patterns appeared 
quite different between the population groups, most notably 
comparing the White and Black population groups. Among 
the White population group, there was an early peak in 
HL incidence rates at ages 20–29 and a later peak around 
age 70–75 with rates somewhat lower and generally stable 
in between these age groups. Among the Black population 
group, there was an increase with HL with age until 
approximately age 30, at which point the rate plateaued 
followed by a subsequent decline beginning around age 
60. For all four major types of hematologic malignancies 
investigated, incidence rates were consistently higher among 
the White population group than the Black population 
group, irrespective of age, but these differences tended to 
increase with age (Fig. 4A–D).
In sensitivity analyses restricted to ages <75, there were 
no marked changes in the results presented in Tables 1-2 
or Figures 1–3. Incidence rate ratios (IRRs) by population 
group were slightly attenuated at ages <75 compared with 
the full adult population, but the reduction was very minor 
and the interpretation unchanged. This observation is 
consistent with the patterns observed in age- specific rates 
whereby differences between the White and Black popula-
tion groups were most apparent at older ages.
Discussion
Summary of key results
The incidence of adult hematologic malignancies (diag-
nosed at ages 15 years or older) was estimated for 
laboratory- confirmed cases reported to the NCR between 
Figure 4. Age- specific rates (per 100,000) of pathology- confirmed (A) leukemia, (B) myeloma, (C) Hodgkin lymphoma, and (D) Non- Hodgkin 
lymphoma reported to the National Cancer Registry of South Africa in 2000–2006 by population group at age ≥15 years, males and females 
combined. Cases with missing gender or population group excluded from analyses.
735© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
South Africa Hematologic MalignanciesS. J. Schonfeld et al.
2000 and 2006, describing overall rates as well as those 
by age, gender, and population group. NHL was the most 
common hematologic malignancy reported to the NCR 
during this time period, irrespective of gender and popu-
lation group. Incidence rates of reported hematologic 
malignancies were generally 20–50% higher among males 
than females. Our analyses suggested lower rates of reported 
hematologic malignancies among the Black population 
group compared with other population groups, with dif-
ferences most pronounced when comparing the White 
and Black population groups. These differences tended 
to become more marked with increasing age. With respect 
to age- specific rates, incidence rates increased with age 
for hematologic malignancies other than HL. For HL, 
among the White population group, a bimodal peak was 
observed at ages 20–29 and 70–75. A different pattern 
was observed among the Black population group; reported 
HL rates increased with age until approximately age 30, 
at which point the rate plateaued, followed by a subse-
quent decline beginning around age 60.
Interpretation of key results
The observation that NHL, followed by leukemia, was 
the most common of these four broad categories of hema-
tologic malignancies is consistent with worldwide patterns 
[1]. The higher incidence rates among males than females 
are also consistent with gender patterns reported elsewhere 
[12, 22].
With respect to population group, age- adjusted incidence 
rates from the U.S. Surveillance, Epidemiology and End 
Results (SEER) 18 registries in the United States for the 
period of 2000–2011 show a predominance among the 
White vs. Black populations with annual White to Black 
ratios (estimated using the SEER Fast Stats tool [23]) of 
1.3–1.5 for NHL, 1.2–1.4 for leukemia and 1.1–1.3 for 
HL. These estimates are somewhat lower than those esti-
mated in the NCR data. Of note, previous analyses of 
the SEER data have shown that the magnitude and direc-
tion of these population group incidence rate ratios varies 
by subtype of leukemia and lymphoma [10, 11]. As we 
did not have full pathology reports for all cases (as dis-
cussed in the Methods) we were not able to consider 
subtypes in this analysis. The apparently distinct age- specific 
patterns observed for HL between the White and Black 
population groups in the NCR data are also reported in 
the SEER data where a clear bimodal pattern, classically 
associated with HL, is much more pronounced in the 
White than Black populations [24]. Globally, the classic 
bimodal age pattern appears to be more a characteristic 
of more economically developed areas [25]. In contrast 
to what is observed for NHL, HL, and leukemia rates, 
the incidence of myeloma in the SEER data is 
approximately twofold greater among the Black than White 
population groups [13]. In contrast, the reported incidence 
rate of myeloma in the NCR was approximately 50% 
greater among the White than Black population groups.
For any cancer site, differences in the underlying dis-
tribution of genetic and environmental risk factors as well 
as factors related to completeness of reporting and diag-
nosis drive demographic variations in the incidence pat-
terns. The etiology of hematologic malignancies is largely 
unexplained, with few known determinants [25–27]. 
Established environmental risk factors for leukemia include 
ionizing radiation and certain chemical exposures such 
as benzene [27]. For NHL, there is clear evidence for an 
association with infectious diseases (HIV, Epstein–Barr 
virus (EBV), Hepatitis C Virus (HCV), and Human 
T- Lymphotrophic Virus (HTLV- 1)) [26] and increasing 
data to support a role for lifestyle, occupational, and 
environmental factors [28]. HL also has an infectious 
etiology – EBV is one of few known risk factors [25]. 
As is common for registry- based studies, we did not have 
individual- level information about risk factors. While we 
cannot exclude the possibility that differences in the dis-
tribution of or susceptibility to etiologic factors could 
explain the marked differences by population group 
observed in the NCR data, the known infectious and 
environmental risk factors would not seem likely explana-
tions. In order for these factors to drive truly higher rates 
of disease within South African White versus Black popu-
lation groups, they would need to be more prevalent in 
the White population group.
Disparities in the completeness of diagnosis and report-
ing between population groups may have contributed to 
the observed incidence rate patterns. The NCR is a pathology- 
based registry and thus only hematologic malignancies with 
a histologic, cytologic, or hematologic (bone marrow aspirate 
or trephine biopsy) confirmation are captured. Consequently, 
there is an inherent risk of under- estimating rates based 
on the registry data as cases diagnosed by other means 
(i.e., peripheral blood smear) are not reported. Problems 
of under- reporting may be compounded, however, by other 
factors that disproportionately affect the Black population 
group compared with the White population group and 
contribute not only to under- reporting but also under- 
diagnosis of these cancers. First, a smaller proportion of 
the Black population group have access to a private medical 
aid fund (7.2% of the Black population versus 63.1% of 
the White population according to 2006 data) [15]. Public 
medical services are chronically under- resourced and under-
staffed [29, 30] and as such, patients in the public sector 
may be less likely than those in the private sector to receive 
a comprehensive diagnostic work- up. Furthermore, the sys-
tem operates under a tiered structure by which patients 
are referred from primary health clinics to tertiary hospitals 
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via other tiers [31] and patients may be lost from the 
system before presenting at referral centers. Factors such 
as distance to the nearest tertiary center [32] may lead to 
delayed or no diagnosis. Second, the burden of HIV varies 
markedly by population group [33]. While HIV is associ-
ated with increased risk of lymphomas, particularly subtypes 
of NHL [9], atypical presentation and histology of HIV- 
associated lymphomas may lead to misdiagnosis or delayed 
diagnosis [34]. In population groups with high HIV rates, 
competing mortality from other causes [9, 35] may reduce 
the opportunity for lymphomas to develop while late- stage 
presentation of disease [3, 36] may lower the chances of 
cancers ever being diagnosed by pathology.
Strengths/limitations
This is the first country- wide study on hematologic malig-
nancies in South Africa and one of very few studies from 
Sub- Saharan Africa. The study benefits from the large 
number of cases permitting detailed examination of rates 
and patterns by age, gender, and population group. The 
diverse population of South Africa enabled us to inves-
tigate differences by population group which is associated 
with socioeconomic circumstances and access to private 
health care in South Africa [15]. Nonetheless, analyses of 
the Asian/Indian and Coloured population groups were 
less robust owing to smaller case numbers than in the 
Black and White population groups, particularly when 
further examining age- specific patterns. Limitations include 
that, by definition, the NCR data being used is restricted 
to pathology- confirmed cancer cases and thus it is under-
stood that it does not fully capture incident hematologic 
malignancies in the country. Furthermore, there was a 
decline in reporting to the NCR by some private sector 
laboratories (beginning in 2005) [16]. This would be 
expected to have the greatest impact on cases reported 
from the White population group which could attenuate 
the observed rate ratios by population group. As discussed 
above, we were unable to implement more detailed subtype 
classification as full pathology reports were not available 
for the period of 2000–2004. Previous studies of lymphoma 
and leukemia in the United States suggest that racial dif-
ferences may vary considerably by subtype [10, 11]. More 
generally, there are known etiologic differences in the 
subtypes of leukemia and lymphomas [26–28]. Once avail-
able, it will be important to repeat these analyses using 
data from more recent years during which full pathology 
reports were received by the NCR. Another limitation is 
that population group had to be imputed for a substantial 
proportion of the dataset. The imputation method, how-
ever, has been previously validated in the NCR and the 
limitation appears to be of minor importance, although 
some misclassification cannot be ruled out. While it is 
important to consider our results in the context of these 
limitations, the NCR provides the most comprehensive 
overview of these cancers in the country at this time.
Conclusions
The hematologic malignancies investigated here collectively 
account for an estimated 6% of new cancer cases and 
8% of cancer deaths in South Africa [1]. The consistency 
of patterns by age and gender with those reported in 
other populations [1, 10, 12, 13, 22, 24] suggest that 
underlying risk factors for these cancers are unlikely to 
modify the age distribution or gender ratio. Differences 
between population groups, however, would appear to be 
more pronounced than those observed in some other set-
tings. We hypothesize that challenges related to diagnosis 
and reporting of cancers play a role in the patterns by 
population group while the set- up of the NCR (pathology- 
based) could lead to some degree of under- ascertainment, 
irrespective of population group, gender, or age. Despite 
challenges, it is important to analyze and report available 
national cancer incidence data to raise awareness of the 
cancer burden and to characterize patterns by demographic 
characteristics so as ultimately to improve the provision 
of cancer diagnosis and care.
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